Epigenomics in Prostate Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (31 May 2021) | Viewed by 2787
Special Issue Editor
Interests: cancer epigenetics; cancer biomarkers; cancer biology & therapeutics; liquid biopsies
Special Issue Information
Dear Colleagues,
Prostate cancer is one of the most common male malignancies in the world. The disease is notorious for its clinical and molecular heterogeneity. It displays a high incidence to mortality ratio, meaning that the majority of men experience a relatively low-risk, latent form of the disease. However, a proportion of tumours have an aggressive nature and hence prostate cancer is the 5th leading cause of cancer-related deaths in men worldwide. It is fair to say that molecular sub-classification of this malignancy has lagged behind that of other solid tumours. The fact that prostate cancer displays an atypically low mutation rate, has undoubtedly contributed to our lack of clarity on hallmark molecular features of aggressive and indolent disease. By contrast, epigenetic alterations are frequent during prostate cancer initiation and progression and indeed the disease is known to undergo an epigenetic catastrophe during the earliest stages of tumour development, with widespread promoter hypermethylation and silencing of regulatory genes. The advent, and now wide availability, of epigenome profiling technologies including array- and sequencing-based platforms has enabled a deep dive into the widespread distortion of the epigenome throughout all stages of prostate cancer.
Accompanying epigenomic alterations in this disease is a dysregulation of many key epigenetic readers, writers and erasers. Significant work in the field has demonstrated numerous regulatory circuits and important relationships between members of the non-coding RNA family, the androgen receptor and its pro-survival signalling pathway with methyltransferases and lysine deacetylases, among others.
This special issue will highlight the central, yet complex, role that epigenomics plays in prostate cancer, from disease development through to castration resistance, and the utility that it offers in disease detection, stratification and prognostication.
Dr. Antoinette S. Perry
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epigenetics
- prostate cancer
- biomarker
- chromatin
- DNA methylation
- ncRNA
- methyltranferase
- deacetylase
- demethylase
- epigenetic therapies
